Kalafo e Ncha ea Motsoako bakeng sa Mathata a Bakiloeng ke Lefu la Lefu la Lefu la Lefu la Cornea

A TSHWARA FreeRelease | eTurboNews | eTN
Avatar ea Linda Hohnholz
ngotsoeng ke Linda Hohnholz

RegeneRx Biopharmaceuticals, Inc. e tlaleha hore bafuputsi ba bontšitse katleho ea phekolo ea Thymosin Beta 4 (Tβ4) e le phekolo e kopantsoeng khahlanong le hyperglycemia (diabetic) -e leng liphetoho tse bakoang ke lisele tsa corneal epithelial.

"Phuputso ea rona e hlakisa khetlo la pele hore kalafo ea motsoako oa Tβ4 le vasoactive intestinal peptide (VIP) e bapala karolo ea bohlokoa ho laolang botsitso bo tiileng le cytoskeleton rearrangement [ea cornea], e amanang haufi-ufi le sethibelo sa botšepehi. Ho feta moo, Tβ4 e tiisa ka matla karolo ea eona e le phekolo ea tlatsetso bakeng sa litšitiso tsa lefu la tsoekere tse se nang litla-morao, kahoo e nolofatsa bofokoli ba mekhoa ea hona joale ea tlhokomelo ea [mahlo], "ho ea ka sehlopha sa lipatlisiso.

Lipatlisiso li ile tsa hlahisoa sebokeng sa Mokhatlo oa Lipatlisiso ka Pono le Ophthalmology (ARVO) 2022, se neng se tšoaretsoe May 1-4, 2022, Denver, Colorado. Sehlopha sa lipatlisiso se ne se kenyelletsa bo-rasaense le lingaka tsa Wayne State University School of Medicine e Detroit, MI; Univesithi ea Central Florida College of Health of Health Professors and Sciences in Orlando, FL; le Univesithi ea Mansoura e Mansoura, Egepeta. Lipatlisiso li ne li tšehetsoa ka lichelete ke Mekhatlo ea Sechaba ea Bophelo bo Botle, Setsi sa Eversight bakeng sa Pono le Lipatlisiso tsa Banka ea Mahlo, le Lipatlisiso ho Thibela Bofofu.

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

  • “Our study elucidates for the first time that a Tβ4 and vasoactive intestinal peptide (VIP) combo treatment plays a crucial role in regulating the tight junction stability and cytoskeleton rearrangement [of the cornea], which are closely related to barrier integrity.
  • The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
  • is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tβ4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells.

Mabapi le mongoli

Avatar ea Linda Hohnholz

Linda Hohnholz

Mohlophisi e ka sehloohong bakeng sa eTurboNews e thehiloe ho eTN HQ.

Subscribe
Tsebiso ea
moeti
0 Comments
Li-feed tsa marang-rang
Sheba maikutlo ohle
0
Ke rata maikutlo a hau, ka kopo fana ka maikutlo.x
()
x
Arolelana ho...